Kerstholt, M
[11] Regulatory and Safety Field for Compounded GLP-1s in 2025 The FDA removed semaglutide from its drug shortage list in early 2025, which has direct legal consequences for 503A and 503B pharmacies that were compounding semaglutide under the shortage exemption
She lives in Puerto Rico
Also READ - Top 5 Apps for Tracking Semaglutide Progress Top GLP-1 gummies for weight loss CRITICAL RULES: Make ONLY the specified edit - do not modify any other text Preserve ALL formatting and line breaks exactly: Keep line breaks in the section content Keep line breaks WITHIN the replacement text If replacement text contains blank lines (line breaks), preserve them exactly Do NOT normalize multi-line text into a single paragraph PRESERVE MARKDOWN LINK SYNTAX: Keep text format for links - do NOT convert to HTML tags DO NOT use HTML entities: Keep & as &, not &, keep " as ", not ", etc
While each peptide has been studied for distinct effects, interest has grown around their combined use, often discussed in orthopedic and sports medicine contexts as part of supportive recovery strategies
Key takeaways: Weight-loss programs, services, and products are usually not qualified expenses for a health savings account (HSA) or a flexible spending account (FSA) unless prescribed for a specific medical condition, such as diabetes or obesity
